No ASX ETF holds Avecho (AVE) as of 15 Oct 2026. Over the last year it rose 114.3%: on $10,000, +$11429. We explain 3 big moves in that time.
About AVE
- SectorHealth Care
- IndustryPharmaceuticals, Biotechnology & Life Sciences
- Size$65.7m
- Held by0 ETFs
- Big moves3 in 1Y
Last year+114.3%
$0.01+114.29% price
Each dot is a move we explain. Tap one, or a row of Why it moved, to see what caused it.
1Y high$0.03
1Y low$0.01
Avg volume7.9m
Latest volume6.4m
Prices to 15 Oct closeNo distributions in this period
Why it moved
3 moves
- +20.0%30 Jun 2026· Sector Flow
Avicho Biotechnology's stock rose 20% likely due to a broad-sector surge in ASX biotech/medical innovation stocks, highlighted by Neuren Pharmaceuticals' 35% jump and subsequent sector-wide investor interest.
- +40.0%24 Jun 2026· Operational
Avecho announced positive interim Phase III insomnia trial results, driving a 40% share price surge.
- +20.0%27 Nov 2025· Unknown
No clear news explains the 20% surge in Avicho Biotechnology shares on 26 Nov 2025; the provided articles are all real estate stories unrelated to the company.
Held by 0 ETFs
No ETF we track holds AVE directly.
Other Health Care companies
- SHLSonic Healthcare47 ETFs
- RMDResMed44 ETFs
- CSLCSL Limited42 ETFs
- BDXBcal36 ETFs
- CSXCleanspace36 ETFs
- REGRegis Health33 ETFs
- TLXTelix Pharma32 ETFs
- SIGSigma Healthcare31 ETFs